ArticleeLife2024
ESAT-6 undergoes self-association at phagosomal pH and an ESAT-6-specific nanobody restricts
Abstract read
In one paragraph
Article in eLife, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- CAR T cell therapy beyond cancer: current status, challenges and future prospects.Signal transduction and targeted therapy · 2026Review
- Mycobacterium tuberculosis lacking CtpF and MmpL7 transporters exhibits altered microbiological traits associated with virulence determinants.Archives of microbiology · 2026Article
- Article
- Evaluation of an ESAT-6 Recombinant Skin Test Reagent for Bovine Tuberculosis Diagnosis in Guinea Pigs and Cattle.International journal of molecular sciences · 2026Article
- A Nanobody-Based Lateral Flow Assay for Point-of-Care Diagnostics.Biosensors · 2026Article
- Macrophage adaptation to hypoxia in the tuberculous granuloma potentiates mycobacterium-induced mitochondrial damage and granuloma necrosis.bioRxiv : the preprint server for biology · 2026Article
- A Conserved Mycobacterial Nucleomodulin Hijacks the Host COMPASS Complex to Reprogram Pro-Inflammatory Transcription and Promote Intracellular Survival.bioRxiv : the preprint server for biology · 2026Article
- Functional analysis of type VII secretion system links to host immune evasion mechanism inFrontiers in cellular and infection microbiology · 2026Review
- Protein-Mediated Virulence in Mycobacterium tuberculosis.Advances in experimental medicine and biology · 2026Review
- Secreted proteins ofFrontiers in tuberculosis · 2026Review
- ESAT-6 and CFP-10 reactive IgG in patients with tuberculosis inhibits intracellular bacteria.Cell reports · 2025Article
- Immunopeptidomics can inform the design of mRNA vaccines for the delivery ofScience translational medicine · 2025Article
- Bioenergetic reprogramming of macrophages reduces drug tolerance in Mycobacterium tuberculosis.Nature communications · 2025Article
- Fundamental role of spatial positioning of Mycobacterium tuberculosis in mycobacterial survival in macrophages.Nature communications · 2025Article
- Stopping Tuberculosis at the Gate: The Role ofVaccines · 2025Review
- Biolayer interferometry for measuring the kinetics of protein-protein interactions and nanobody binding.Nature protocols · 2025Review
- Real-time visualization reveals Mycobacterium tuberculosis ESAT-6 disrupts phagosome-like compartment via fibril-mediated vesiculation.Cell reports · 2025Article
- Nanobodies in animal infectious disease control: diagnosis and therapy.Frontiers in cellular and infection microbiology · 2025Review
- Antigen specificity shapes antibody functions in tuberculosis.bioRxiv : the preprint server for biology · 2024Article
- ESAT-6 undergoes self-association at phagosomal pH and an ESAT-6-specific nanobody restrictseLife · 2024Article
Corrections and comments
- Update of
Authors and funding
16 authors.
Timothy A BatesDepartment of Molecular Microbiology and Immunology, Oregon Health & Sciences University, Portland, United States.ORCID 0000-0002-2533-7668
Mila Trank-GreeneDepartment of Molecular Microbiology and Immunology, Oregon Health & Sciences University, Portland, United States.
Xammy Huu WrynlaDepartment of Molecular Microbiology and Immunology, Oregon Health & Sciences University, Portland, United States.ORCID 0000-0002-7532-8356
Aidan AnastasDepartment of Molecular Microbiology and Immunology, Oregon Health & Sciences University, Portland, United States.
Sintayehu K GurmessaDepartment of Molecular Microbiology and Immunology, Oregon Health & Sciences University, Portland, United States.
Ilaria R MerutkaDepartment of Molecular Microbiology and Immunology, Oregon Health & Sciences University, Portland, United States.
Shandee D DixonDepartment of Molecular Microbiology and Immunology, Oregon Health & Sciences University, Portland, United States.
Anthony ShumateDepartment of Chemical Physiology and Biochemistry, Oregon Health & Science University, Portland, United States.
Abigail R GronckiDepartment of Molecular Microbiology and Immunology, Oregon Health & Sciences University, Portland, United States.
Matthew A H ParsonDepartment of Biochemistry and Microbiology, University of Victoria, Victoria, Canada.ORCID 0000-0001-6270-559X
Jessica R IngramProgram in Cellular and Molecular Medicine, Boston Children's Hospital, Harvard Medical School, Boston, United States.
Eric BarklisDepartment of Molecular Microbiology and Immunology, Oregon Health & Sciences University, Portland, United States.
John E BurkeDepartment of Biochemistry and Microbiology, University of Victoria, Victoria, Canada.ORCID 0000-0001-7904-9859
Ujwal ShindeDepartment of Chemical Physiology and Biochemistry, Oregon Health & Science University, Portland, United States.
Hidde L PloeghProgram in Cellular and Molecular Medicine, Boston Children's Hospital, Harvard Medical School, Boston, United States.
Fikadu G TafesseDepartment of Molecular Microbiology and Immunology, Oregon Health & Sciences University, Portland, United States.ORCID 0000-0002-8575-4164
Funding
Multidisciplinary Research Training in Pulmonary MedicineT32HL083808 · NHLBI · OREGON HEALTH & SCIENCE UNIVERSITY · PI LEWINSOHN, DAVID M., SLATORE, CHRISTOPHER G. · 2008 to 2025
$5.3MDetermining the role of sphingolipids in Mycobacterium tuberculosis infectionR01AI141549 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI TAFESSE, FIKADU G. · 2020 to 2025
$2.4MOctet Red384S10OD023413 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI BARR-GILLESPIE, PETER GORDON · 2017 to 2017
$318kBill and Melinda Gates Foundation OPP1179922CIHR 168998Michael Smith Health Research BC 17686NHLBI NIH HHS 5T32HL083808NHLBI NIH HHS T32 HL083808NIAID NIH HHS R01 AI141549NIH HHS R01AI141549NIH HHS S10 OD023413OHSU Biophysics Shared Resources Core and equipment S10OD023413
Abstract
PubMed holds no abstract for this paper.
Indexed as
Antigens, BacterialBacterial ProteinsMacrophagesMycobacterium tuberculosisPhagosomesSingle-Domain AntibodiesHumansHydrogen-Ion ConcentrationMolecular Dynamics SimulationAntigens, BacterialBacterial ProteinsESAT-6 protein, Mycobacterium tuberculosisSingle-Domain AntibodiesbiochemistryCFP-10chemical biologyESAT-6humaninfectious diseasemicrobiologyM. tuberculosisNanobodyVHH
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.